Comparative Pharmacology
Head-to-head clinical analysis: DEPOCYT versus HYDREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPOCYT versus HYDREA.
DEPOCYT vs HYDREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is a nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and cell death in the S phase of the cell cycle.
Hydroxyurea inhibits ribonucleotide reductase, thereby reducing the conversion of ribonucleotides to deoxyribonucleotides, which impairs DNA synthesis and leads to cell cycle arrest in S phase. It also induces fetal hemoglobin (HbF) production by increasing nitric oxide and soluble guanylyl cyclase activity.
50 mg intrathecally via lumbar puncture or intraventricularly via Ommaya reservoir on days 1, 15, 29, 43, 57, 71, 85, and 99 for induction; followed by consolidation and maintenance doses. Administer with dexamethasone 4 mg PO/IV twice daily for 5 days starting on the day of DepoCyt injection.
20-30 mg/kg orally once daily; typical adult dose 500 mg to 1.5 g daily. Maximum dose 2 g per day.
None Documented
None Documented
After intrathecal administration, the terminal half-life of cytarabine in CSF is 2.5-4.5 hours (mean 3.5 hours) due to slow clearance from CSF; systemic half-life is 10-15 minutes due to rapid deamination.
The terminal elimination half-life is approximately 3-4 hours in patients with normal renal function. In patients with creatinine clearance <60 mL/min, half-life may be prolonged up to 8-12 hours, necessitating dose adjustment.
Renal excretion of cytarabine metabolites accounts for >70% of elimination; unchanged cytarabine excretion is minimal (<10%). Biliary/fecal excretion is negligible (<5%).
Renal excretion is the primary route of elimination, with 50-80% of an administered dose recovered as unchanged drug in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Antineoplastic
Antineoplastic